

Detection of lupus anticoagulant in the era of direct oral

Autoimmunity Reviews

16, 173-178

DOI: [10.1016/j.autrev.2016.12.010](https://doi.org/10.1016/j.autrev.2016.12.010)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Autoimmunity in 2016. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 53, 126-139.	6.5	9
2	Anti-phospholipid syndrome: Current opinion on mechanisms involved, laboratory characterization and diagnostic aspects. <i>Transfusion and Apheresis Science</i> , 2017, 56, 612-625.	1.0	10
3	Arterial stenosis in antiphospholipid syndrome: Update on the unrevealed mechanisms of an endothelial disease. <i>Autoimmunity Reviews</i> , 2018, 17, 256-266.	5.8	9
4	Antiphospholipid syndrome. <i>Nature Reviews Disease Primers</i> , 2018, 4, 17103.	30.5	233
6	Perioperative Thromboelastometry for Adult Living Donor Liver Transplant Recipients with a Tendency to Hypercoagulability: A Prospective Observational Cohort Study. <i>Transfusion Medicine and Hemotherapy</i> , 2018, 45, 404-412.	1.6	26
7	Prevalence and Significance of Non-conventional Antiphospholipid Antibodies in Patients With Clinical APS Criteria. <i>Frontiers in Immunology</i> , 2018, 9, 2971.	4.8	65
8	Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2018, 78, 575-583.	1.2	13
9	The clinical value of assays detecting antibodies against domain I of Î²2-glycoprotein I in the antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2018, 17, 1210-1218.	5.8	27
10	Falseâ€positive lupus anticoagulant results by <scp>DRVVT</scp> in the presence of rivaroxaban even at low plasma concentrations. <i>International Journal of Laboratory Hematology</i> , 2018, 40, e99-e101.	1.3	9
11	Autoimmunity in 2017. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 55, 239-253.	6.5	5
12	Diagnostics and treatment of thrombotic antiphospholipid syndrome (APS): A personal perspective. <i>Thrombosis Research</i> , 2018, 169, 35-40.	1.7	31
13	Evaluation of the DOAC-StopÂ® Procedure to Overcome the Effect of DOACs on Several Thrombophilia Screening Tests. <i>TH Open</i> , 2018, 02, e202-e209.	1.4	54
14	A diagnostic solution for haemostasis laboratories for patients taking direct oral anticoagulants using DOACâ€Remove. <i>British Journal of Haematology</i> , 2019, 187, 377-385.	2.5	30
15	Lupus anticoagulant diagnosis in patients receiving direct oral FXa inhibitors at trough levels: A realâ€life study. <i>International Journal of Laboratory Hematology</i> , 2019, 41, 738-744.	1.3	9
16	Potential usefulness of activated charcoal (DOAC removeÂ®) for dRVVT testing in patients receiving Direct Oral AntiCoagulants. <i>Thrombosis Research</i> , 2019, 184, 86-91.	1.7	30
17	Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961987255.	1.7	25
18	Autoantibodies in Disease Criteria for Systemic Autoimmune Diseases. , 2019, , 81-89.		0
19	Routine Coagulation Tests in Patients With Nonvalvular Atrial Fibrillation Under Dabigatran and Rivaroxaban Therapy: An Affordable and Reliable Strategy?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961983505.	1.7	5

#	ARTICLE	IF	CITATIONS
20	Evaluation of an automated algorithm for interpretation of lupus anticoagulant testing. <i>International Journal of Laboratory Hematology</i> , 2019, 41, 412-417.	1.3	7
21	The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1374-1381.	2.3	39
22	The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases. <i>Autoimmunity Reviews</i> , 2019, 18, 406-414.	5.8	106
23	Antiphospholipid syndrome in pediatric patients. <i>Current Opinion in Hematology</i> , 2019, 26, 366-371.	2.5	8
24	Effects and interferences of emicizumab, a humanized bispecific antibody mimicking activated factor VIII cofactor function, on lupus anticoagulant assays. <i>International Journal of Laboratory Hematology</i> , 2020, 42, e71-e75.	1.3	6
25	The effect of unfractionated heparin, enoxaparin, and danaparoid on lupus anticoagulant testing: Can activated carbon eliminate false-positive results?. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 161-168.	2.3	29
26	Consultative Interpretation for Lupus Anticoagulant by Expert Pathologist Reduces False-Positive Rates in the Era of Direct Oral Anticoagulants. <i>Journal of Applied Laboratory Medicine</i> , The, 2020, 5, 73-82.	1.3	2
27	Oral anticoagulants in thrombotic antiphospholipid syndrome: Leave the old road for a new trail?. <i>European Journal of Internal Medicine</i> , 2020, 79, 29-30.	2.2	1
28	Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2828-2839.	3.8	211
29	Additional laboratory tests to improve on the diagnosis of antiphospholipid syndrome: Response from Pengo. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3118-3119.	3.8	10
30	New Insights into the Use of Direct Oral Anticoagulants in Non-high Risk Thrombotic APS Patients: Literature Review and Subgroup Analysis from a Meta-analysis. <i>Current Rheumatology Reports</i> , 2020, 22, 25.	4.7	6
31	Evaluation of DOAC Filter, a new device to remove direct oral anticoagulants from plasma samples. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 636-642.	1.3	19
32	Testing for antiphospholipid antibodies: Advances and best practices. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 49-58.	1.3	22
33	How to Interpret Antiphospholipid Laboratory Tests. <i>Current Rheumatology Reports</i> , 2020, 22, 38.	4.7	25
34	Unveiling the complex effects of direct oral anticoagulants on dilute Russell's viper venom time assays. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1866-1873.	3.8	14
35	Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1569-1575.	3.8	76
36	The Effect of Direct Oral Anticoagulants on Antithrombin Activity Testing Is Abolished by DOAC-Stop in Venous Thromboembolism Patients. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 99-104.	2.5	8
37	DOAC-Stop in lupus anticoagulant testing: Direct oral anticoagulant interference removed in most samples. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 314-325.	2.3	14

#	ARTICLE	IF	CITATIONS
38	Autoimmune Coagulation Factor X Deficiency as a Rare Acquired Hemorrhagic Disorder: A Literature Review. <i>Thrombosis and Haemostasis</i> , 2022, 122, 320-328.	3.4	13
39	Anti-phosphatidyl-serine/prothrombin antibodies (aPS/PT) in isolated lupus anticoagulant (LA): is their presence linked to dual test positivity?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1950-1953.	2.3	13
40	In vitro diagnostics for the medical dermatologist. Part II: Hypercoagulability tests. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 301-310.	1.2	2
41	Correlation Analysis of Anti-Cardiolipin Antibody/D Dimer/C-Reactive Protein and Coronary Artery Lesions/Multiple-Organ Damage in Children With Kawasaki Disease. <i>Frontiers in Pediatrics</i> , 2021, 9, 704929.	1.9	3
42	Antiphospholipid syndrome – an update. <i>Vasa - European Journal of Vascular Medicine</i> , 2018, 47, 451-464.	1.4	58
43	Direct oral anticoagulant adsorption: Impact on lupus anticoagulant testing – Review of the literature and evaluation on spiked and patient samples. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2003-2017.	3.8	27
44	Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL. <i>Blood Transfusion</i> , 2018, 16, 462-470.	0.4	54
45	Anti-Phosphatidylserine/Prothrombin Antibodies at Two Points: Correlation With Lupus Anticoagulant and Thrombotic Risk. <i>Frontiers in Immunology</i> , 2021, 12, 754469.	4.8	13
46	Consensus sulla diagnostica di laboratorio per i pazienti in trattamento con farmaci anticoagulanti ad azione diretta. Sottoscritto dalla Società Italiana per lo Studio dell'Emostasi e della Trombosi (SISET), dalla Federazione Centri per la diagnosi della trombosi e la Sorveglianza delle terapie Antitrombotiche (FCSA), dalla Società Italiana di Biochimica Clinica e Biologia Molecolare Clinica (SIBioC) e dalla Società Italiana di Patologia Clinica e Medicina di Laboratorio (SIPMeL). <i>Rivista Italiana Della Medicina Di Laboratorio</i> , 2019, 15.	0.4	0
47	A Meta-analysis and Systematic Review of Valvular Heart Disease in Systemic Lupus Erythematosus and Its Association With Antiphospholipid Antibodies. <i>Journal of Clinical Rheumatology</i> , 2021, 27, e525-e532.	0.9	13
48	Guidelines for lupus anticoagulant testing in South Africa. <i>The Journal of Medical Laboratory Science & Technology of South Africa</i> , 2020, 2, 6-12.	0.1	1
49	Predicting coronary graft occlusion in males with type 2 diabetes: an annual prospective study. <i>Kuban Scientific Medical Bulletin</i> , 2020, 27, 189-200.	0.4	0
50	Influence of DOACS and DOAC-REMOVE® on coagulation assays during thrombophilia testing in DOAC-treated patients. <i>Vojnosanitetski Pregled</i> , 2022, 79, 1248-1254.	0.2	0
51	Evaluation of Activated Carbon Treatment on Overcoming the Interference of Rivaroxaban on the Detection of Functional Lupus Anticoagulant. <i>Acta Haematologica</i> , 2022, , .	1.4	0
52	Direct Oral Anticoagulant removal by a DOAC filter: Impact on lupus anticoagulant testing – Evaluation on spiked and patient samples. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12633.	2.3	9
53	Antiphospholipid Antibodies and Lipids in Hematological Malignancies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4151.	4.1	9
54	Investigation of the Molecular Mechanism of Coagulopathy in Severe and Critical Patients With COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 762782.	4.8	4
55	Recent Advances in Anticoagulant Treatment of Immune Thrombosis: A Focus on Direct Oral Anticoagulants in Heparin-Induced Thrombocytopenia and Anti-Phospholipid Syndrome. <i>International Journal of Molecular Sciences</i> , 2022, 23, 93.	4.1	8

#	ARTICLE	IF	CITATIONS
61	Antibodies to the phosphatidylserine/prothrombin complex in the diagnosis of antiphospholipid syndrome. <i>Terapevticheski Arkhiv</i> , 2022, 94, 628-634.	0.8	0
62	Antiphospholipid Syndrome in Patients with Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 833-839.	2.7	3
63	Thrombin generation assay and lupus anticoagulant synergically distinguish populations of patients with antiphospholipid antibodies. <i>Journal of Clinical Pathology</i> , 2023, 76, 839-846.	2.0	3
64	â€œHow we treatâ€•clinical dilemmas in antiphospholipid syndrome: A case-based approach. <i>European Journal of Internal Medicine</i> , 2022, , .	2.2	0
65	Direct oral anticoagulant adsorption and laboratory detection of lupus anticoagulant. <i>Blood Coagulation and Fibrinolysis</i> , 2023, 34, 199-205.	1.0	1
66	Laboratory Diagnosis of Antiphospholipid Syndrome in Anticoagulated Patients. <i>Biomedicines</i> , 2023, 11, 1760.	3.2	4
67	Considerations for simultaneous detection of autoantibodies to coagulation factor and lupus anticoagulant. <i>Exploration of Immunology</i> , 0, , 286-299.	0.3	0
68	Removing direct oral factor Xa inhibitor interferences from routine and specialised coagulation assays using a raw activated charcoal product. <i>Clinica Chimica Acta</i> , 2023, 550, 117565.	1.1	2
69	Antiphospholipid syndrome and kidney involvement. <i>Kidney and Blood Pressure Research</i> , 0, , .	2.0	0
70	16th International congress on antiphospholipid antibodies task force report on antiphospholipid syndrome laboratory diagnostics and trends. <i>Lupus</i> , 2023, 32, 1625-1636.	1.6	1
71	Viewpoint: Lupus anticoagulant detection and interpretation in antiphospholipid syndrome. <i>Rheumatology</i> , 2024, 63, S154-S163.	1.9	1